NCT04446507View on ClinicalTrials.gov

A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 27, 2020

Primary Completion Date

May 28, 2024

Study Completion Date

May 28, 2024

Conditions
Renal Impairment
Interventions
DRUG

Saroglitazar magnesium

1 dose of 2mg and 4 mg Saroglitazar magnesium will be given to subjects on Day 1

Trial Locations (2)

32720

Zydus US003, DeLand

78215

Zydus US001, San Antonio

All Listed Sponsors
lead

Zydus Therapeutics Inc.

INDUSTRY

NCT04446507 - A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function | Biotech Hunter | Biotech Hunter